Viral myocarditis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Viral myocarditis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function https://clinicaltrials.eu/trial/study-on-the-use-of-methylprednisolone-sodium-succinate-for-treating-patients-with-acute-myocarditis-and-mildly-reduced-heart-function/ Wed, 29 Apr 2026 14:57:15 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-methylprednisolone-sodium-succinate-for-treating-patients-with-acute-myocarditis-and-mildly-reduced-heart-function/ This clinical trial is focused on studying the treatment of acute myocarditis, a condition where the heart muscle becomes inflamed, which can affect the heart’s ability to pump blood effectively. The study will use a treatment called Solu-Medrone, which is a type of medication known as a corticosteroid. Corticosteroids are often used to reduce inflammation in the body. In this study, Solu-Medrone will be given as an injection into the bloodstream. Some participants will receive this treatment, while others will receive a placebo, which looks like the treatment but does not contain the active medication.

The purpose of the study is to see if the corticosteroid treatment can improve heart function in patients with acute myocarditis. Participants will be randomly assigned to receive either the Solu-Medrone treatment or the placebo. The study will last for a few days, during which the heart’s function will be monitored using tests like an echocardiogram, which is an ultrasound of the heart. This will help doctors see if the treatment is effective in improving the heart’s ability to pump blood.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on whether corticosteroid therapy can be a beneficial treatment for patients with acute myocarditis, potentially leading to better outcomes for those affected by this condition.

]]> Study on Anakinra for Treating Virus-Negative Myocarditis in Patients https://clinicaltrials.eu/trial/study-on-anakinra-for-treating-virus-negative-myocarditis-in-patients/ Wed, 29 Apr 2026 14:23:02 +0000 https://clinicaltrials.eu/trial/study-on-anakinra-for-treating-virus-negative-myocarditis-in-patients/ This clinical trial is focused on studying a heart condition called virus-negative myocarditis. This condition involves inflammation of the heart muscle that is not caused by a virus. The study is testing a treatment that includes a medication called anakinra, which is an IL-1 inhibitor, meaning it helps reduce inflammation by blocking a specific protein in the body. The treatment will be given in addition to the standard care, which includes medications like azathioprine and prednisone, commonly used to suppress the immune system and reduce inflammation.

The purpose of the study is to evaluate the benefit of adding anakinra to the standard treatment for virus-negative myocarditis. Participants in the study will receive either anakinra or a placebo, along with the standard care. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving anakinra and who is receiving the placebo. This helps ensure that the results are not biased. The treatment will be administered through subcutaneous use, which means it is injected under the skin.

The study will last for a period of six months, during which the participants’ heart function will be monitored. This will be done using a test called Trans Thoracic Echocardiography (TTE), which is a type of ultrasound that looks at how well the heart is pumping. The main goal is to see if the treatment can improve the heart’s ability to pump blood, measured by something called the Left Ventricular Ejection Fraction (LVEF). The study aims to provide valuable information on whether anakinra can be a beneficial addition to the treatment of virus-negative myocarditis.

]]>